SubHero Banner

Tecentriq® (atezolizumab) – Expanded indication

June 19, 2018 - The FDA approved Genentech’s Tecentriq (atezolizumab), for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for cisplatin-containing chemotherapy, and whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the tumor area), or are not eligible for any platinum-containing chemotherapy regardless of level of tumor PD-L1 expression.

Download PDF